• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Novel protocols of inhaled GM-CSF therapy for smoker patients with pulmonary alveolar proteinosis

Research Project

Project/Area Number 20H03686
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypeSingle-year Grants
Section一般
Review Section Basic Section 53030:Respiratory medicine-related
Research InstitutionTokyo Medical and Dental University

Principal Investigator

TAZAWA Ryushi  東京医科歯科大学, 学生支援・保健管理機構, 教授 (70301041)

Co-Investigator(Kenkyū-buntansha) 石井 晴之  杏林大学, 医学部, 教授 (30406970)
中田 光  新潟大学, 医歯学総合病院, 特任教授 (80207802)
田中 崇裕  新潟大学, 医歯学総合病院, 助教 (70455400)
小松崎 恵子  東京医科歯科大学, 職員健康管理室, 助教 (50867306)
Project Period (FY) 2020-04-01 – 2024-03-31
Project Status Completed (Fiscal Year 2023)
Budget Amount *help
¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2023: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2022: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2021: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2020: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
KeywordsGM-CSF / 抗GM-CSF抗体 / GM-CSF吸入治療 / 肺胞蛋白症 / リツキシマブ / 吸入治療 / 気道被覆液 / 移流 / 薬物動態 / 抗体産生抑制 / 喫煙
Outline of Research at the Start

2000年に申請者は世界に先駆け重症の自己免疫性肺胞蛋白症患者にGM-CSF吸入療法を実施し、寛解に導いた。ついで、早期Ⅱ相、多施設Ⅱ相試験 へと進み、2016-17年に全国12施設での医師主導偽薬対照ランダム化比較試験で本治療の有効性と安全性をに報告した。問題は喫煙・既喫煙患者で、本治療が効きにくいことである。予備的検討では、喫煙・既喫煙者では、GM-CSF吸入により病因とされている抗GM-CSF自己抗体の産生が亢進していた。本研究では臨床検体とカニクイザルモデルを用いて,この機序を解明し、抗GM-CSF自己抗体産生を抑制しつつ、GM-CSF吸入投与を行う改良型治療プロトコルを開発する。

Outline of Final Research Achievements

We conducted the following studies on granulocyte-macrophage colony-stimulating factor (GM-CSF) inhalation therapy for autoimmune pulmonary alveolar proteinosis (aPAP), which Japanese authority recently approved. A search for positive cases in other diffuse lung diseases revealed a few positive cases in patients with hypersensitivity pneumonitis. We attempted to rhGM-CSF inhalation treatment in combination with rituximab to suppress anti-GM-CSF antibodies in four cynomolgus monkeys at a fully AAALAC certified facility under the approval of the Animal Experiment Ethics Committees. The animals completed treatment without any serious side effects, and the antibody production was suppressed at the initial stage of the inhalation. To consider an efficient inhalation method, we created a mathematical model for the pharmacokinetics of GM-CSF from the respiratory tract to the bloodstream, suggesting the importance of drug deposition in the bronchi and advection to the alveoli.

Academic Significance and Societal Importance of the Research Achievements

aPAPに対するGM-CSF吸入製剤は本年薬機法による製造販売承認がおりて今後実地臨床での使用が進められるが、その際に大きく参考となる研究成果が得られた。診断に有用な抗GM-CSF抗体について知見が得られ、GM-CSF気道投与とリツキサン静脈注射の併用の可能性がカニクイザルで検討され、効率のよい吸入方法を考えるため、過去の非臨床試験データを基盤に、分子量の大きいGM-CSF製剤の気道~血中への薬物動態の数理モデルが作成され、1回換気量や呼吸回数が吸気の薬剤濃度・滞留時間に影響することが示唆された。

Report

(5 results)
  • 2023 Annual Research Report   Final Research Report ( PDF )
  • 2022 Annual Research Report
  • 2021 Annual Research Report
  • 2020 Annual Research Report
  • Research Products

    (15 results)

All 2024 2023 2022 2021 2020

All Journal Article (7 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 6 results,  Open Access: 5 results) Presentation (6 results) (of which Int'l Joint Research: 2 results,  Invited: 3 results) Book (2 results)

  • [Journal Article] Short-term inhalation of sargramostim with concomitant high-dose steroids does not hasten recovery in moderate COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trial2023

    • Author(s)
      Shimasaki S, Baba T, Ogura T, Akasaka K, Matsushima H, Izumi S, Takasaki J, Tsushima K, Kinouchi T, Kichikawa Y, Awashima M, Izumo T, Awano N, Nishimura N, Tazawa R, Mikami A, Kitamura N, Ishii H, Kurihara Y, Taniguchi M, Aikawa S, Okada M, Morita Y, Ishikawa Y, Ohinata A, Nakata K
    • Journal Title

      Infectious Disease

      Volume: 55(12) Issue: 12 Pages: 857-873

    • DOI

      10.1080/23744235.2023.2254380

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] COVID-19 in patients with pulmonary alveolar proteinosis: a European multicentre study.2023

    • Author(s)
      Papiris SA, Campo I, Mariani F, Kallieri M, Kolilekas L, Papaioannou AI, Gonca Chousein E, Cetinkaya E, Bonella F, Borie R, (25名略)Kanaka-Gantenbein C, Karakatsani A, Loukides S, Costabel U, Crestani B, Morgan C, Tazawa R, Bush A, Griese M, Manali ED.
    • Journal Title

      ERJ Open Res.

      Volume: 9 Issue: 1 Pages: 00199-2022

    • DOI

      10.1183/23120541.00199-2022

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Quantitative Evaluation of Changes in Three-Dimensional CT Density Distributions in Pulmonary Alveolar Proteinosis after GM-CSF Inhalation.2023

    • Author(s)
      8.Oda M, Yamaura K, Ishii H, Kitamura N, Tazawa R, Abe M, Tatsumi K, Eda R, Kondoh S, Morimoto K, Tanaka T, Yamaguchi E, Takahashi A, Izumi S, Sugiyama H, Nakagawa A, Tomii K, Suzuki M, Konno S, Ohkouchi S, Tode N, Handa T, Hirai T, Inoue Y, Arai T, Asakawa K, Tanaka T, Takada T, Nonaka H, Nakata K
    • Journal Title

      Respiration

      Volume: 102(2) Issue: 2 Pages: 101-109

    • DOI

      10.1159/000528038

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Metabolic and Epigenetic Regulation of SMAD7 by STC1 Ameliorates Lung Fibrosis2022

    • Author(s)
      Ohkouchi Shinya、Kanehira Masahiko、Saigusa Daisuke、Ono Manabu、Tazawa Ryushi、Terunuma Hideya、Hirano Taizou、Numakura Tadahisa、Notsuda Hirotsugu、Inoue Chihiro、Saito-Koyama Ryoko、Tabata Masao、Irokawa Toshiya、Ogawa Hiromasa、Kurosawa Hajime、Okada Yoshinori
    • Journal Title

      American Journal of Respiratory Cell and Molecular Biology

      Volume: 67 Issue: 3 Pages: 320

    • DOI

      10.1165/rcmb.2021-0445oc

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Genetic determinants of risk in autoimmune pulmonary alveolar proteinosis2021

    • Author(s)
      Sakaue S, Yamaguchi E, Inoue Y, Handa T, Tanizawa K, Ishii H, Ishida M, Kato T, Takeda N, Yokomura K, Matsui T, Watanabe M, Inoue H, Imaizumi K, Goto Y, Kida H, Fujisawa T, Suda T, Yamada T, Satake Y, Ibata H, Hizawa N, Mochizuki H, Kumanogoh A, Matsuda F, Nakata K, Hirota T, Tamari M, Okada Y
    • Journal Title

      Nature Communications

      Volume: 12 Issue: 1 Pages: 1032-1032

    • DOI

      10.1038/s41467-021-21011-y

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] 肺胞蛋白症とGM-CSF吸入治療2021

    • Author(s)
      田澤立之
    • Journal Title

      日本内科学会雑誌

      Volume: 110 Pages: 1918-1925

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed
  • [Journal Article] 【免疫・炎症疾患のすべて】免疫・炎症疾患各論/呼吸器疾患 肺胞蛋白症(PAP)2020

    • Author(s)
      田澤立之
    • Journal Title

      日本医師会雑誌

      Volume: 149巻特別2

    • Related Report
      2020 Annual Research Report
  • [Presentation] 最適な吸入方法とは? ―吸入数理モデルから言えること―2024

    • Author(s)
      田澤立之
    • Organizer
      第64回日本呼吸器学会学術講演会 シンポジウム「GM-CSF承認後の自己免疫性肺胞蛋白症診療」・S1
    • Related Report
      2023 Annual Research Report
    • Invited
  • [Presentation] 自己免疫性肺胞蛋白症に対するGM-CSF吸入法の 最適化を目指した数理モデルの構築2024

    • Author(s)
      田澤立之 北村信隆 田中崇裕 高澤聖子 石井晴之
    • Organizer
      第64回日本呼吸器学会学術講演会 ミニシンポジウム「びまん性肺疾患 稀な疾患」・MS82
    • Related Report
      2023 Annual Research Report
  • [Presentation] Two-year cohort study after GM-CSF inhalation therapy for autoimmune pulmonary alveolar proteinosis2023

    • Author(s)
      Koh Nakata, Ryushi Tazawa, Page Research Group, Nobutaka Kitamura
    • Organizer
      European Respiratory Society International Congress 2023
    • Related Report
      2023 Annual Research Report
    • Int'l Joint Research
  • [Presentation] 肺胞蛋白症とGM-CSF吸入療法2022

    • Author(s)
      田澤立之
    • Organizer
      第43回日本臨床薬理学会学術総会シンポジウム「難治性呼吸器疾患に対する吸入療法の新展開」2022年12月2日
    • Related Report
      2022 Annual Research Report
    • Invited
  • [Presentation] 肺胞蛋白症とGM-CSF吸入治療2021

    • Author(s)
      田澤立之
    • Organizer
      第118回日本内科学会講演会
    • Related Report
      2021 Annual Research Report
    • Invited
  • [Presentation] Antibody Against Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and Inhaled GM-CSF for Pulmonary Alveolar Proteinosis.2020

    • Author(s)
      R. Tazawa, (11名略)H. Ishii, (15名略) T. Tanaka, T. Takada, A. Mikami, N. Kitamura, K. Nakata.
    • Organizer
      ATS 2020 Virtual American Thoracic Society International Conference
    • Related Report
      2020 Annual Research Report
    • Int'l Joint Research
  • [Book] 呼吸器疾患最新の治療2023-20242023

    • Author(s)
      田澤立之「肺胞蛋白症」 in 弦間昭彦、西岡安彦、矢寺和博 編集
    • Total Pages
      516
    • Publisher
      南江堂
    • Related Report
      2022 Annual Research Report
  • [Book] 今日の治療指針 2022年版[デスク判]2022

    • Author(s)
      田澤立之「肺胞蛋白症」 in 福井 次矢、高木 誠、小室 一成 総編集
    • Total Pages
      2224
    • Publisher
      医学書院
    • ISBN
      9784260047760
    • Related Report
      2021 Annual Research Report

URL: 

Published: 2020-04-28   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi